期刊文献+

贝伐珠单抗联合紫杉醇、奈达铂治疗卵巢癌晚期效果及对血清炎性因子及免疫指标影响 被引量:23

Effect of bevacizumab combined with paclitaxel,nedaplatin for treating patients with advanced ovarian cancer,and its influence on their serum inflammatory cytokines and immune indexes
下载PDF
导出
摘要 目的:探讨紫杉醇、奈达铂联合贝伐珠单抗治疗卵巢癌晚期效果及对血清炎性因子及免疫指标影响。方法:随机数字表法将本院2017年5月—2019年5月收治的卵巢癌晚期患者82例分为对照组(贝伐珠单抗治疗)和联合组(贝伐珠单抗联合紫杉醇、奈达铂治疗)。比较两组治疗后患者免疫细胞、炎性因子、肿瘤标志物水平、血清肝癌衍生生长因子(HDGF)、巨噬细胞移动抑制因子(MIF)、转化生长因子(TGF)-β1水平。结果:治疗后联合组免疫细胞水平高于对照组,白介素6(IL-6)、IL-10、血管内皮生长因子水平低于对照组,IL-2和干扰素-γ水平高于对照组,肿瘤标志物水平低于对照组,血清HDGF、MIF、TGF-β1水平低于对照组(均P<0.05)。结论:贝伐珠单抗联合紫杉醇、奈达铂治疗晚期卵巢恶性病变效果理想,可有效改善患者免疫细胞和肿瘤标志物水平,降低炎性因子水平,利于患者病情恢复。 Objective:To investigate the effect Effect of paclitaxel,nedaplatin combined with bevacizumab for treating patients with advanced ovarian cancer,and to study its influence on their serum inflammatory cytokines and immune indexes.Methods:82 patients with advanced ovarian cancer were divided into control group(patients with bevacizumab treatment)and study group(patients with paclitaxel,nedaplatin combined with bevacizumab treatment)according to the random number table method from May 2017 to May 2019.The levels of immune cells,inflammatory cytokines,tumor markers,and the levels of serum HDGF,MIF,and TGF-1 of patients were compared between the two groups.Results:The level of immune cells of patients in the study group was significant higher than that of patients in the control group(P<0.05).After treatment,the levels of IL-6,IL-10 and VEGF of patients in the study group were significant lower than those of patients in the control group(P<0.05),while the levels of IL-2 and INF-γof patients in the study group were significant higher.The levels of tumor marker,and serum HDGF,MIF and TGF-1 of patients in the study group were significant higher than those of patients in the control group(all P<0.05).Conclusion:Paclitaxel,nedaplatin combined with bevacizumab for treating patients with advanced ovarian cancer has ideal effect,which can effectively improve the level of immune cells and tumor markers,reduce the level of inflammatory factors,and is conducive to the recovery of patients.
作者 葛艳 于韬 邱爽 吴冬梅 GE Yan;YU Tao;QIU Shuang;WU Dongmei(Municipal Hospital affiliated to Xuzhou Medical University, Xuzhou, Jiangsu Province, 221000)
出处 《中国计划生育学杂志》 2020年第12期2030-2033,2037,共5页 Chinese Journal of Family Planning
关键词 卵巢癌晚期 贝伐珠单抗 紫杉醇 奈达铂 免疫细胞 炎性因子 肿瘤标志物 Advanced ovarian cancer Bevacizumab Paclitaxel Nida's platinum Immune cells Inflammatory cytokines Tumor marker
  • 相关文献

参考文献15

二级参考文献100

共引文献152

同被引文献225

引证文献23

二级引证文献36

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部